I very much doubt they will abandon the study. Remember that the issue with the GLP drugs is primarily affecting recruitment. If they lower the recruitment target, they can still get close to meeting timelines. And @jellyroll made this point earlier - these other drugs can assist with weight loss but they do not reduce ICP... there's still a need here in IIH. These other GLPs will not eliminate obesity, and even if they could, it wouldn't necessarily impact the incidence of IIH
Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-78
-
- There are more pages in this discussion • 147 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable